Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Genocea Biosciences Inc    GNCA

GENOCEA BIOSCIENCES INC

(GNCA)
My previous session
Most popular
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector news

GENOCEA BIOSCIENCES, INC. (NASDAQ:GNCA) Files An 8-K Entry into a Material Definitive Agreement

share with twitter share with LinkedIn share with facebook
share via e-mail
0
02/12/2019 | 09:13am EST

GENOCEA BIOSCIENCES, INC. (NASDAQ:GNCA) Files An 8-K Entry into a Material Definitive Agreement
Item 1.01

Entry into a Material Definitive Agreement.

On February 11, 2019, Genocea Biosciences, Inc. (the “Company”) entered into a Subscription Agreement (the “Subscription Agreement”) with certain purchasers identified on the pages thereto (the “Purchasers”), to which the Company will offer to the Purchasers, in an unregistered offering, shares of common stock, par value $0.001 per share (the “Common Stock”), and warrants to purchase shares of Common Stock, in two closings.

The first closing is anticipated to occur on February 14, 2019 (the “Initial Closing”), subject to the satisfaction of customary closing conditions. The Company will offer 25,599,979 shares of Common Stock and, to one Purchaser and its affiliates in lieu of shares of Common Stock, a pre-funded warrant to purchase 4,250,000 shares of common stock (the “Pre-Funded Warrant”), and accompanying warrants (the “Warrants” and together with the Common Stock and Pre-Funded Warrants, the “Units”) to purchase an aggregate of 7,462,494 shares of Common Stock (the “Warrant Shares”) at a purchase price of $0.5026 per Unit for aggregate gross proceeds to the Company of approximately $15.0 million, before deducting fees to the placement agents and other estimated offering expenses payable by the Company. The Warrants will expire five (5) years following the Initial Closing (subject to early termination as noted below), will have an exercise price of $0.5656 per Warrant Share, and are immediately exercisable upon issuance. The Pre-Funded Warrants will expire twenty (20) years following the Initial Closing, will have an exercise price of $0.01 per share, and are immediately exercisable upon issuance. The exercise price and number of shares of Common Stock issuable upon the exercise of the Warrants and the Pre-Funded Warrants will be subject to adjustment in the event of any stock dividends and splits, reverse stock split, recapitalization, reorganization or similar transaction, as described in the Warrants and the Pre-Funded Warrants.

Contingent upon satisfactory top-line results from Part A of its Phase 1/2a clinical trial for its lead cancer vaccine candidate, GEN-009 (the “Data”), the Company will have the option to conduct a second closing (the “Second Closing”) and will offer up to an additional $24.2 million in shares of Common Stock to the Purchasers at a purchase price per share that is equal to the greater of $0.4713 per share and a per share price that is derived from the volume weighted average price of the Common Stock from the date the Company releases the Data through the date the Company exercises of its option to proceed with the Second Closing. If a Purchaser does not purchase at least 50% of the shares of Common Stock that it specified to purchase in the Second Closing (each such Purchaser, a “Non-Participating Purchaser”), it will forfeit any unexercised Warrants purchased in the first Closing as the Company’s sole remedy for such failure. The other Purchasers that are not Non-Participating Purchasers will have the option, but not the obligation, to purchase the shares of Common Stock allocated to the Non-Participating Purchasers in the Second Closing.

The Company will file a resale registration statement with the Securities and Exchange Commission (the “SEC”) as soon as practicable, and in all events within 60 days after the Initial Closing, to register the resale of the securities issued at the time of the Initial Closing or issuable in connection with the Second Closing.

Cantor Fitzgerald & Co. is acting as the lead placement agent for the Company in connection with the offering. Robert W. Baird & Co. Incorporated, Needham & Company LLC and H.C. Wainwright & Co., LLC are acting as co-placement agents for the Company in connection with the offering.

The foregoing summaries of the offering, the securities to be issued in connection therewith, the Subscription Agreement, the Pre-Funded Warrants and the Warrants do not purport to be complete and are qualified in their entirety by reference to the definitive transaction documents. Copies of the forms of Pre-Funded Warrant and the Warrant are attached hereto as Exhibits 4.1 and 4.2, respectively, and are incorporated herein by reference. The foregoing description of the Subscription Agreement does not purport to be complete and is qualified in its entirety by reference to the Subscription Agreement, a copy of which the Company intends to file with the SEC as an exhibit to its Quarterly Report on Form 10-Q for the quarter ended March 31, 2019.

On February 12, 2019, the Company issued a press release announcing the offering described above, a copy of which is attached hereto as Exhibit 99.1.

Item 3.02 Unregistered Sales of Equity Securities.

To the extent required by Item 3.02 of Form 8-K, the information regarding the Common Stock and Warrants set forth under Item 1.01 of this Form 8-K is incorporated by reference in this Item 3.02. The Company issued the Common Stock and Warrants in reliance on the exemption from registration provided for under Section 4(a)(2) of the Securities Act of 1933, as amended (the “Securities Act”). The Company relied on this exemption from registration for private placements based in part on the representations made by the Purchasers, including the representations with respect to each Purchaser’s status as an accredited investor, as such term is defined in Rule 501(a) of the Securities Act, and each Purchaser’s investment intent.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

GENOCEA BIOSCIENCES, INC. Exhibit
EX-4.1 2 ex41_pre-fundedwarrant.htm EXHIBIT 4.1 Exhibit NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933,…
To view the full exhibit click here

About GENOCEA BIOSCIENCES, INC. (NASDAQ:GNCA)

Genocea Biosciences, Inc. is a biopharmaceutical company. The Company discovers and develops vaccines and immunotherapies. It uses its discovery platform, AnTigen Lead Acquisition System (ATLAS), to design vaccines and immunotherapies that act, in part, through T cell (or cellular) immune responses. The Company operates through business of developing and commercializing vaccines segment. It has one product candidate in Phase II clinical development: GEN-003, which is a therapeutic vaccine or immunotherapy for the treatment of genital herpes infections. It has pre-clinical development programs, which include GEN-001, which is indicated for the treatment of chlamydia prophylaxis, and GEN-002, which indicated for the treatment of genital herpes prophylaxis both of which are in pre-clinical stage of development. The Company’s pipeline also includes GEN-005, which is under malaria prophylaxis, Epstein-Barr virus and immuno-oncology programs in research stage of development.

The post GENOCEA BIOSCIENCES, INC. (NASDAQ:GNCA) Files An 8-K Entry into a Material Definitive Agreement appeared first on Market Exclusive.

© Market Exclusive 2019, source Market Exclusive

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on GENOCEA BIOSCIENCES INC
08:18aGENOCEA TO HOST QUARTERLY CORPORATE : 00 am ET
PU
08:02aGENOCEA TO HOST QUARTERLY CORPORATE : 00 am ET
GL
02/12GENOCEA BIOSCIENCES, INC. : Unregistered Sale of Equity Securities, Financial St..
AQ
02/12Genocea Announces Private Placement Financing of Up to $39 Million
GL
01/07GENOCEA BIOSCIENCES, INC. : Regulation FD Disclosure, Financial Statements and E..
AQ
01/02Genocea Doses First Patients and Completes Enrollment in Part A of Phase 1/2a..
GL
2018GENOCEA BIOSCIENCES, INC. : Notice of Delisting or Failure to Satisfy a Continue..
AQ
2018Genocea Appoints Girish Aakalu, Ph.D., Chief Business Officer
GL
2018Genocea To Host a Key Opinion Leader Event November 26th on Latest Advances i..
GL
2018GENOCEA BIOSCIENCES : Unveils Possible Mechanism for Tumor Resistance to Immunot..
PU
More news
Financials ($)
Sales 2018 -
EBIT 2018 -41,2 M
Net income 2018 -39,2 M
Debt 2018 -
Yield 2018 -
P/E ratio 2018 -
P/E ratio 2019
Capi. / Sales 2018 0
Capi. / Sales 2019 0
Capitalization 43,3 M
Chart GENOCEA BIOSCIENCES INC
Duration : Period :
Genocea Biosciences Inc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends GENOCEA BIOSCIENCES INC
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 3
Average target price 3,67 $
Spread / Average Target 633%
EPS Revisions
Managers
NameTitle
William D. Clark President, Chief Executive Officer & Director
Katrine S. Bosley Chairman
Michael Alfieri VP-Finance, Chief Financial & Accounting Officer
Jessica Baker Flechtner Chief Scientific Officer
Thomas Andrew Davis Chief Medical Officer
Sector and Competitors
1st jan.Capitalization (M$)
GENOCEA BIOSCIENCES INC74.34%43
IQVIA HOLDINGS INC22.11%28 245
CELLTRION, INC.--.--%24 286
LONZA GROUP13.78%21 553
INCYTE CORPORATION32.33%17 924
SEATTLE GENETICS, INC.26.16%11 201